Posatex ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

posatex

intervet international bv - orbifloxacin, mometasone furoate, posaconazole - otoloģijas - suņi - Ārstēšana akūta vidusauss externa un akūtu exacerbations periodiskās otīts externa, kas saistīts ar baktēriju, kas uzņēmīgi pret orbifloxacin un sēnītes, kas ir uzņēmīgas pret posaconazole, jo īpaši malassezia pachydermatis.

Neptra ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

neptra

bayer animal health gmbh - florfenikols, terbinafine hidrohlorīds, mometasone furoate - otologicals, kortikosteroīdiem un antiinfectives kopā - suņi - lai ārstētu akūtu suņu otīts externa vai akūtas exacerbations periodiskās otīts, ko izraisa jauktas infekcijas uzņēmīgi baktēriju celmi jutīgas pret florfenikols (staphylococcus pseudintermedius) un sēnes jutīgas pret terbinafine (malassezia pachydermatis).

Enerzair Breezhaler ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - zāles obstruktīvu elpceļu slimību, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Bemrist Breezhaler ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited  - indacaterol, mometasone furoate - astma - zāles obstruktīvu elpceļu slimību, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Atectura Breezhaler ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

atectura breezhaler

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - zāles obstruktīvu elpceļu slimību, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Zimbus Breezhaler ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

zimbus breezhaler

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - zāles obstruktīvu elpceļu slimību, - maintenance treatment of asthma in adults whose disease is not adequately controlled.